Clinical assessment of cerebral vasospasm risk following aneurysmal subarachnoid hemorrhage
US12157918B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 7, 2021 |
| Grant date | Dec 3, 2024 |
| Priority date | — |
| Expiry date | Aug 19, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/178
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A treatment method for cerebral vasospasm involves determining amounts of let-7b-5p, miR-9-3p, miR-142-3p, miR-15b-5p, miR-17-5p, miR-19b-3p, miR-20a-5p, miR-24-3p, miR-29a-3p, miR-125b-5p, and miR-142-3p in a biological sample obtained from a subject following aneurysmal subarachnoid hemorrhage (aSAH) to identify the subject as having an elevated risk of cerebral vasospasm, and administering a treatment to the subject when the elevated risk of cerebral vasospasm is identified.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.